Earnings ·
Alamar Biosciences reported second quarter 2026 financial results with total revenue of $29.4 million, an 82% increase…
ALMRAlamar Biosciences, Inc.
Alamar Biosciences reported second quarter 2026 financial results with total revenue of $29.4 million, an 82% increase from the prior year period. Consumable revenue surged 147% to $15.5 million, while instrument revenue grew 35% to $7.8 million and services revenue increased 49% to $6.2 million. The company reported a net loss of $13.2 million compared to $7.0 million in the prior year period, with operating expenses rising 89% to $31.2 million due to investments in headcount and R&D. Gross margin improved to 60% from 53%. Alamar provided full-year 2026 revenue guidance of $116 million to $120 million. The company maintains a cash position of $256.3 million as of June 30, 2026. Alamar Biosciences operates in the biotechnology and diagnostics industry, specializing in precision proteomics for disease detection.